ES2988617T3 - Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales - Google Patents

Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales Download PDF

Info

Publication number
ES2988617T3
ES2988617T3 ES17849505T ES17849505T ES2988617T3 ES 2988617 T3 ES2988617 T3 ES 2988617T3 ES 17849505 T ES17849505 T ES 17849505T ES 17849505 T ES17849505 T ES 17849505T ES 2988617 T3 ES2988617 T3 ES 2988617T3
Authority
ES
Spain
Prior art keywords
subject
hypercytokinemia
dosage form
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17849505T
Other languages
English (en)
Spanish (es)
Inventor
Robin Parish Hyde-Deruyscher
Nancy Harlan Hyde-DeRuyscher
Elicia Kristine Hyde-DeRuyscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergo Therapeutics Inc
Original Assignee
Emergo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergo Therapeutics Inc filed Critical Emergo Therapeutics Inc
Application granted granted Critical
Publication of ES2988617T3 publication Critical patent/ES2988617T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
ES17849505T 2016-09-08 2017-09-07 Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales Active ES2988617T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662385021P 2016-09-08 2016-09-08
PCT/US2017/050409 WO2018048989A1 (en) 2016-09-08 2017-09-07 Mast cell stabilizers for treatment of hypercytokinemia and viral infection

Publications (1)

Publication Number Publication Date
ES2988617T3 true ES2988617T3 (es) 2024-11-21

Family

ID=61281984

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17849505T Active ES2988617T3 (es) 2016-09-08 2017-09-07 Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales

Country Status (15)

Country Link
US (5) US10501527B2 (enExample)
EP (1) EP3509596B1 (enExample)
JP (1) JP2019529541A (enExample)
KR (1) KR20190073365A (enExample)
CN (1) CN109952101A (enExample)
AU (2) AU2017325010A1 (enExample)
BR (1) BR112019004496A2 (enExample)
CA (1) CA3036230A1 (enExample)
ES (1) ES2988617T3 (enExample)
IL (1) IL265208A (enExample)
MX (1) MX389999B (enExample)
MY (1) MY204310A (enExample)
PH (1) PH12019500513A1 (enExample)
RU (1) RU2760682C2 (enExample)
WO (1) WO2018048989A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR20190044647A (ko) 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
KR20190073365A (ko) 2016-09-08 2019-06-26 이메르고 테라퓨틱스, 인코포레이티드 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제
JP2019533018A (ja) 2016-10-18 2019-11-14 エマーゴ セラピューティクス，インク． 慢性炎症状態の処置の為の肥満細胞安定剤
WO2020051322A1 (en) * 2018-09-05 2020-03-12 The General Hospital Corporation Methods of treating cytokine release syndrome
CA3122989A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
US20200268734A1 (en) * 2019-02-22 2020-08-27 Bridge Pharma, Inc. Methods of treatment of respiratory disorders
US10959992B2 (en) 2019-02-22 2021-03-30 Bridge Pharma Inc. Methods of treatment of asthma and COPD
US20230346848A1 (en) * 2020-03-06 2023-11-02 Figene, Llc Fibroblast and tlr activated fibroblast treatment of viral induced acute respiratory distress syndrome
JP2023520580A (ja) * 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
WO2023278381A1 (en) * 2021-06-29 2023-01-05 Bridge Pharma, Inc. Treatment of dermal cytokine storm syndromes

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
AU6165798A (en) 1997-02-18 1998-09-08 Bridge Pharma, Inc. Non-sedating histamine antagonist compounds, compositions and methods of use thereof
BR9807911A (pt) 1997-04-03 2000-02-22 Bridge Pharma Inc Compostos benzocicloheptatiofeno
US6207684B1 (en) * 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
CA2283603A1 (en) 1998-10-01 2000-04-01 Paul W. Behnke Forced closed-loop cooling for a submersible pump motor
AU782816B2 (en) 1999-09-13 2005-09-01 Bridge Pharma, Inc. Optically active isomers of ketotifen and therapeutically active metabolites thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20030118670A1 (en) * 2001-07-11 2003-06-26 Smith C. Steven Novel composition and method for altering allergenic protein in the environment
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
US20060084695A1 (en) 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
JP2009517404A (ja) 2005-11-28 2009-04-30 メディミューン，エルエルシー Ｈｍｇｂ１および／またはｒａｇｅのアンタゴニストならびにその使用方法
CN104614873A (zh) 2006-09-29 2015-05-13 庄臣及庄臣视力保护公司 用于治疗眼变态反应性的方法和眼科装置
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
EP2214503A1 (en) 2007-10-15 2010-08-11 Revolymer Limited Solvent-free synthesis of amphiphilic polymeric material
CN101821989A (zh) 2007-12-24 2010-09-01 中兴通讯股份有限公司 一种光传输系统的通道共享保护方法及装置
CN101990437A (zh) * 2008-01-04 2011-03-23 阿尔康药品有限公司 稳定的环孢菌素水性组合物
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
US8741930B2 (en) 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
CA2754996A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
CA2780453A1 (en) 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
HUE033063T2 (hu) 2010-05-14 2017-11-28 Abbvie Inc IL-1 kötõ fehérjék
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP2014520847A (ja) 2011-07-13 2014-08-25 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用して喘息を治療するための方法および組成物
WO2014040112A1 (en) 2012-09-17 2014-03-20 Guina Research & Development Pty Ltd Electromagnetic turbine
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US20140120121A1 (en) 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US9347325B2 (en) 2012-10-31 2016-05-24 Solar Turbines Incorporated Damper for a turbine rotor assembly
JP6084473B2 (ja) 2013-02-01 2017-02-22 日立オートモティブシステムズ株式会社 複合センサ
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9138431B2 (en) * 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US10293352B2 (en) 2015-02-13 2019-05-21 Kärcher North America, Inc. Hand held fluid dispensing apparatus
CA2976369A1 (en) 2015-02-13 2016-08-18 Yale University Biaryltriazole inhibitors of macrophage migration inhibitory factor
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
US9694003B2 (en) 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
KR20190073365A (ko) 2016-09-08 2019-06-26 이메르고 테라퓨틱스, 인코포레이티드 사이토카인 과분비 및 바이러스성 감염의 치료를 위한 비만 세포 안정화제
JP2019533018A (ja) 2016-10-18 2019-11-14 エマーゴ セラピューティクス，インク． 慢性炎症状態の処置の為の肥満細胞安定剤

Also Published As

Publication number Publication date
CN109952101A (zh) 2019-06-28
AU2017325010A1 (en) 2019-03-28
US20180066039A1 (en) 2018-03-08
KR20190073365A (ko) 2019-06-26
AU2023204000A1 (en) 2023-07-13
PH12019500513A1 (en) 2019-05-27
MY204310A (en) 2024-08-22
US20190085057A1 (en) 2019-03-21
EP3509596A1 (en) 2019-07-17
US10494420B2 (en) 2019-12-03
US10787502B2 (en) 2020-09-29
RU2019110150A (ru) 2020-10-08
EP3509596B1 (en) 2024-07-03
IL265208A (en) 2019-05-30
MX2019002781A (es) 2019-09-04
JP2019529541A (ja) 2019-10-17
EP3509596A4 (en) 2020-05-06
RU2760682C2 (ru) 2021-11-29
US20180072796A1 (en) 2018-03-15
CA3036230A1 (en) 2018-03-15
US20200055926A1 (en) 2020-02-20
RU2019110150A3 (enExample) 2020-12-18
EP3509596C0 (en) 2024-07-03
WO2018048989A1 (en) 2018-03-15
MX389999B (es) 2025-03-11
US20200055927A1 (en) 2020-02-20
US10501527B2 (en) 2019-12-10
BR112019004496A2 (pt) 2019-05-28
US10160796B2 (en) 2018-12-25
US11072648B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
ES2830447T3 (es) Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
Imran et al. Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
AR077484A1 (es) Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion
JP2018502128A (ja) 真菌感染を阻害するための組成物および方法
EA037085B1 (ru) Композиция для устранения заложенности носа, обладающая противовирусным действием
KR20120107970A (ko) 상승적 항바이러스 조성물 및 이의 용도
AU2016287580A1 (en) Compositions and methods for the treatment of viral infection
Popov et al. Combined therapy of influenza with antiviral drugs with a different mechanism of action in comparison with monotherapy
CN104321061B (zh) 依立托伦或其药学上可接受的盐在制备治疗正粘病毒感染的药物中的用途
JP2013510838A (ja) 微生物感染症の治療
EP3936132A1 (en) Azelastine as antiviral treatment
CN117979991A (zh) 使用药物和疫苗接种组合治疗的用于治疗、改善或预防感染的方法
HK40011695B (en) Norketotifen for treatment of hypercytokinemia and viral infections
HK40011695A (en) Norketotifen for treatment of hypercytokinemia and viral infections
CN106507666A9 (zh) 1，3‑丙二磺酸或其药学上可接受的盐用于治疗肉样瘤病的用途
CN104473932A (zh) 治疗中枢神经系统炎症性脱髓鞘疾病的药物组合物及其联合给药的用途
JP2019533018A (ja) 慢性炎症状態の処置の為の肥満細胞安定剤
US20210346459A1 (en) Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs
JP6153193B2 (ja) アレルギー性疾患の予防または治療のための医薬組成物
CN117460738A (zh) 冠状病毒感染的预防和治疗
JP2024507417A (ja) イヌパルボウイルス感染を治療するための組成物および方法
ITMI20011863A1 (it) Associazione di farmaci contro il virus dell'influenza
BR112018012195B1 (pt) Uso de 2-[4-(1,1-dimetiletil)fenil]-1h-benzimidazol, ou um sal farmaceuticamente aceitável do mesmo
HK40036124A (en) Methods of using dipivefrin